Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/ROCK2_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/ROCK2_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/ROCK2_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Endometrium/ROCK2_pca_on_diff_genes.png) | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/ROCK2_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/ROCK2_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/ROCK2_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/ROCK2_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/ROCK2_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/ROCK2_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0039694 | Liver | HCC | viral RNA genome replication | 22/7958 | 35/18723 | 1.21e-02 | 4.41e-02 | 22 |
GO:000704312 | Liver | HCC | cell-cell junction assembly | 76/7958 | 146/18723 | 1.23e-02 | 4.47e-02 | 76 |
GO:011002022 | Liver | HCC | regulation of actomyosin structure organization | 54/7958 | 100/18723 | 1.33e-02 | 4.76e-02 | 54 |
GO:000166721 | Liver | HCC | ameboidal-type cell migration | 226/7958 | 475/18723 | 1.35e-02 | 4.81e-02 | 226 |
GO:00098968 | Lung | IAC | positive regulation of catabolic process | 114/2061 | 492/18723 | 4.93e-15 | 1.25e-11 | 114 |
GO:00313318 | Lung | IAC | positive regulation of cellular catabolic process | 98/2061 | 427/18723 | 7.79e-13 | 9.25e-10 | 98 |
GO:00071637 | Lung | IAC | establishment or maintenance of cell polarity | 61/2061 | 218/18723 | 3.10e-12 | 3.07e-09 | 61 |
GO:00160328 | Lung | IAC | viral process | 94/2061 | 415/18723 | 5.11e-12 | 4.27e-09 | 94 |
GO:00070447 | Lung | IAC | cell-substrate junction assembly | 36/2061 | 95/18723 | 6.81e-12 | 4.27e-09 | 36 |
GO:00071607 | Lung | IAC | cell-matrix adhesion | 63/2061 | 233/18723 | 7.08e-12 | 4.27e-09 | 63 |
GO:00300107 | Lung | IAC | establishment of cell polarity | 46/2061 | 143/18723 | 7.70e-12 | 4.27e-09 | 46 |
GO:00315897 | Lung | IAC | cell-substrate adhesion | 85/2061 | 363/18723 | 8.57e-12 | 4.27e-09 | 85 |
GO:00480416 | Lung | IAC | focal adhesion assembly | 34/2061 | 87/18723 | 9.46e-12 | 4.27e-09 | 34 |
GO:00518937 | Lung | IAC | regulation of focal adhesion assembly | 29/2061 | 66/18723 | 1.01e-11 | 4.27e-09 | 29 |
GO:00901097 | Lung | IAC | regulation of cell-substrate junction assembly | 29/2061 | 66/18723 | 1.01e-11 | 4.27e-09 | 29 |
GO:00190588 | Lung | IAC | viral life cycle | 77/2061 | 317/18723 | 1.23e-11 | 4.83e-09 | 77 |
GO:19033117 | Lung | IAC | regulation of mRNA metabolic process | 71/2061 | 288/18723 | 3.76e-11 | 1.24e-08 | 71 |
GO:01501157 | Lung | IAC | cell-substrate junction organization | 36/2061 | 101/18723 | 5.37e-11 | 1.52e-08 | 36 |
GO:01501167 | Lung | IAC | regulation of cell-substrate junction organization | 29/2061 | 71/18723 | 8.86e-11 | 2.29e-08 | 29 |
GO:00019527 | Lung | IAC | regulation of cell-matrix adhesion | 40/2061 | 128/18723 | 4.69e-10 | 9.93e-08 | 40 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0513020 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa0541720 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516318 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
hsa0513120 | Cervix | CC | Shigellosis | 69/1267 | 247/8465 | 7.64e-08 | 1.03e-06 | 6.10e-07 | 69 |
hsa0520516 | Cervix | CC | Proteoglycans in cancer | 60/1267 | 205/8465 | 9.13e-08 | 1.18e-06 | 7.00e-07 | 60 |
hsa0451010 | Cervix | CC | Focal adhesion | 59/1267 | 203/8465 | 1.53e-07 | 1.84e-06 | 1.09e-06 | 59 |
hsa0481016 | Cervix | CC | Regulation of actin cytoskeleton | 64/1267 | 229/8465 | 2.24e-07 | 2.59e-06 | 1.53e-06 | 64 |
hsa0452020 | Cervix | CC | Adherens junction | 33/1267 | 93/8465 | 6.99e-07 | 7.31e-06 | 4.32e-06 | 33 |
hsa0453020 | Cervix | CC | Tight junction | 49/1267 | 169/8465 | 1.87e-06 | 1.78e-05 | 1.05e-05 | 49 |
hsa0467020 | Cervix | CC | Leukocyte transendothelial migration | 36/1267 | 114/8465 | 5.22e-06 | 4.83e-05 | 2.86e-05 | 36 |
hsa0513516 | Cervix | CC | Yersinia infection | 39/1267 | 137/8465 | 3.27e-05 | 2.41e-04 | 1.42e-04 | 39 |
hsa0407110 | Cervix | CC | Sphingolipid signaling pathway | 35/1267 | 121/8465 | 5.70e-05 | 3.93e-04 | 2.32e-04 | 35 |
hsa043609 | Cervix | CC | Axon guidance | 47/1267 | 182/8465 | 8.13e-05 | 5.38e-04 | 3.18e-04 | 47 |
hsa043109 | Cervix | CC | Wnt signaling pathway | 43/1267 | 171/8465 | 3.03e-04 | 1.64e-03 | 9.68e-04 | 43 |
hsa04062 | Cervix | CC | Chemokine signaling pathway | 43/1267 | 192/8465 | 3.60e-03 | 1.34e-02 | 7.91e-03 | 43 |
hsa049218 | Cervix | CC | Oxytocin signaling pathway | 34/1267 | 154/8465 | 1.12e-02 | 3.42e-02 | 2.02e-02 | 34 |
hsa046115 | Cervix | CC | Platelet activation | 28/1267 | 124/8465 | 1.50e-02 | 4.45e-02 | 2.63e-02 | 28 |
hsa05130110 | Cervix | CC | Pathogenic Escherichia coli infection | 63/1267 | 197/8465 | 9.28e-10 | 2.00e-08 | 1.19e-08 | 63 |
hsa05417110 | Cervix | CC | Lipid and atherosclerosis | 65/1267 | 215/8465 | 6.47e-09 | 1.10e-07 | 6.52e-08 | 65 |
hsa0516319 | Cervix | CC | Human cytomegalovirus infection | 65/1267 | 225/8465 | 4.59e-08 | 6.47e-07 | 3.83e-07 | 65 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ROCK2 | SNV | Missense_Mutation | novel | c.3226N>C | p.Lys1076Gln | p.K1076Q | O75116 | protein_coding | deleterious(0) | probably_damaging(0.946) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | rs747260728 | c.1715N>A | p.Arg572Gln | p.R572Q | O75116 | protein_coding | tolerated(0.38) | benign(0.065) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | | c.3560N>A | p.Ser1187Asn | p.S1187N | O75116 | protein_coding | tolerated(0.16) | benign(0.097) | TCGA-AN-A0FL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | | c.4091G>C | p.Arg1364Thr | p.R1364T | O75116 | protein_coding | deleterious(0.01) | benign(0.041) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | | c.1849N>C | p.Glu617Gln | p.E617Q | O75116 | protein_coding | tolerated(0.34) | benign(0.083) | TCGA-BH-A0HP-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | doxorubicin | SD |
ROCK2 | SNV | Missense_Mutation | novel | c.2329N>C | p.Glu777Gln | p.E777Q | O75116 | protein_coding | tolerated(0.67) | benign(0.028) | TCGA-PE-A5DE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
ROCK2 | SNV | Missense_Mutation | novel | c.186N>C | p.Leu62Phe | p.L62F | O75116 | protein_coding | deleterious(0.02) | probably_damaging(0.95) | TCGA-XX-A89A-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK2 | insertion | Nonsense_Mutation | novel | c.2665_2666insCAATTTAACTATAATCCAA | p.Glu889AlafsTer3 | p.E889Afs*3 | O75116 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ROCK2 | SNV | Missense_Mutation | novel | c.712A>C | p.Lys238Gln | p.K238Q | O75116 | protein_coding | deleterious(0) | probably_damaging(0.929) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
ROCK2 | SNV | Missense_Mutation | | c.2719N>A | p.Glu907Lys | p.E907K | O75116 | protein_coding | deleterious(0) | probably_damaging(0.957) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 178102655 | | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | AR-12286 | VEROSUDIL | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | BAY-613606 | CHEMBL541400 | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | AST-487 | AST-487 | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | THROMBIN | THROMBIN | 16720831 |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 178101973 | | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | KD025 | | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | VER-49009 | CHEMBL365617 | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | | Tricyclic compound 4 | | |
9475 | ROCK2 | KINASE, ENZYME, DRUGGABLE GENOME, SERINE THREONINE KINASE | inhibitor | 310264692 | VEROSUDIL | |